Insurer alleges Queens pharmacy ran $2.8M No-Fault scheme on three drugs

One pharmacy. Three drugs. 91% of the billing. And an OTC alternative costs about $10
Insurer alleges Queens pharmacy ran $2.8M No-Fault scheme on three drugs
RISK, COMPLIANCE & LEGAL
By Tez Romero
Nov 20, 2026

What happened: GEICO alleges a Queens pharmacy ran a $2.8 million No-Fault billing scheme dispensing three high-priced drugs to crash victims under predetermined protocols

Who's involved: GEICO (plaintiff insurer) and Quick Script Chemist Inc. (defendant pharmacy)

What's at stake: Approximately $613,000 already paid, plus a declaration voiding roughly $2 million in pending claims, with triple damages sought under federal racketeering law

Why it matters: The alleged pattern - 91% billing concentration in three products, identical prescriptions for patients in the same crash - offers a case study in pharmacy fraud red flags for No-Fault claims teams

Where it stands: Complaint filed November 19, 2026, in the Eastern District of New York

An over-the-counter lidocaine pain product sells for about $10 at major retailers. According to a new federal lawsuit, a Queens pharmacy was billing GEICO $1,524 a prescription for a higher-strength version - and that was the cheapest item on its menu.

GEICO filed suit on November 19, 2026, in the US District Court for the Eastern District of New York, alleging that Quick Script Chemist Inc. ran a large-scale fraud scheme through New York's No-Fault auto insurance system. The complaint says the pharmacy submitted approximately $2.8 million in claims to GEICO, overwhelmingly for three high-priced drugs dispensed to car crash patients.

The filing alleges the pharmacy targeted Diclofenac Sodium 2% Solution, Lidocaine 5% Ointment, and a combined naproxen-esomeprazole tablet - billing GEICO $2,149.50, $1,524, and $2,144.64 per prescription respectively. Those three products, according to the complaint, made up about 91% of everything the pharmacy billed.

The $10 question

What makes those numbers stand out is what else is on the shelf. The complaint notes that over-the-counter products containing 4% lidocaine - which it describes as offering similar pain-relief properties - are available at major retailers for approximately $10. The Diclofenac Sodium 2% Solution, the filing states, is only FDA-approved to treat pain from osteoarthritis of the knees. Yet the complaint alleges the pharmacy dispensed it to car accident patients with no documented history of that condition.

The naproxen-esomeprazole product, marketed under the brand name Vimovo, combines a pain reliever with a stomach-acid reducer. The FDA says it should not be used as a first treatment for sudden pain, the complaint notes. Each of its ingredients is available without a prescription at a fraction of the cost.

GEICO alleges the pharmacy acquired these products cheaply and billed at prices pegged to inflated wholesale benchmarks.

Same crash, same prescriptions

The complaint lays out what it calls a pattern of cookie-cutter prescribing. In multiple examples, two or more patients involved in the same car accident were allegedly prescribed the identical combination of drugs - regardless of their age, physical condition, or where they were sitting in the vehicle.

In one instance, the filing alleges, three patients from a single January 2025 accident each received Lidocaine 5% Ointment, Diclofenac Sodium 2% Solution, and cyclobenzaprine - all purportedly prescribed by one practitioner, even though a different provider had actually examined them. In another, four patients from a New Year's Day 2025 accident were allegedly given the same drug combination over successive months.

Prescriptions were also routinely dated days after the supposed examinations rather than at the time of the visit, the complaint says. In one case, the filing states, a prescription was written 13 days after the patient was seen.

A pharmacy with a narrow menu

Quick Script Chemist was incorporated in March 2024 and registered as a pharmacy that May, according to the complaint. GEICO alleges that in its first year, the pharmacy submitted approximately $707,000 in billing to GEICO alone - without maintaining a website, running any advertising, or doing anything a typical community pharmacy would do to attract customers.

About 70% of patients who allegedly received drugs from the pharmacy lived outside Queens, where it is located, the complaint says. Some resided as far away as Westchester, Orange, and Rockland counties. Others lived outside New York entirely - in New Jersey, Connecticut, and Pennsylvania.

GEICO alleges that roughly 63% of the pharmacy's billing was based on prescriptions from just two medical practices. Both of those practices and their associated practitioners have been the subject of prior insurer fraud lawsuits, according to the complaint, which cites multiple earlier federal cases.

The filing further alleges the pharmacy's purported owner is the spouse of a named defendant in a separate federal fraud action involving a different pharmacy that received prescriptions for similar products from some of the same prescribers.

What GEICO wants back

The insurer says it has already paid approximately $613,000 on the pharmacy's claims. It is asking the court to confirm it owes nothing on roughly $2 million in pending bills and to award triple damages under federal racketeering law - which would bring the recovery sought on the paid claims alone to approximately $1.839 million. The complaint also seeks punitive damages.

GEICO's suit alleges the pharmacy violated New York's anti-kickback law for pharmacy referrals and brings federal racketeering, fraud, and unjust enrichment claims. RICO - the Racketeer Influenced and Corrupt Organizations Act - allows plaintiffs who prove a pattern of fraud conducted through an enterprise to recover three times their actual losses.

No-Fault insurers are increasingly tracking pharmacy-level billing patterns, and a narrow product mix paired with outsized billing volume relative to a pharmacy's age can quickly draw this kind of suit.

The allegations in the complaint have not been tested, and no court has ruled on the merits.

Related Stories
Free newsletter

We'll keep you up-to-date with the latest breaking news, cutting edge opinion, and expert analysis affecting both your business and the industry as whole.

Free newsletter

Our daily newsletter is FREE and keeps you up - to - date with the world of Insurance. Please complete the form below and click on subscribe for daily newsletters from IB US.